Catalyst Event

Shanghai Junshi Biosciences Co Ltd (1877) · Other

From Akros SCHK HK-Global Brain-Computer Interface Index (ASHGBCI)

4/26/2026, 12:00:00 AM

OtherSentiment: Positive

Positive preliminary clinical results for JS207 (PD-1/VEGF) and JS212 (EGFR/HER3) at 2026 AACR; medium importance estimated as clinical progress is likely to cause a 5-10% price impact scheduled.

Korean Translation

2026년 AACR에서 JS207(PD-1/VEGF) 및 JS212(EGFR/HER3) 임상 결과 발표; 임상 진전에 따른 5~10% 수준의 주가 영향이 예정됨.

Related Recent Events

View Full Timeline